Navigation Links
Mylan Pharmaceuticals Receives Final FDA Report and Reaffirms Its 48-Year Exemplary Record of Quality
Date:8/13/2009

PITTSBURGH, Aug. 13 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that the U.S. Food and Drug Administration (FDA) has released its official and final report regarding the agency's review of allegations made in a July newspaper article concerning the company's Morgantown, W.Va., manufacturing facility. The newspaper article, which included unfounded and highly inaccurate allegations, was based on improperly obtained documents, uninformed third-party commentary and anonymous sources. The final FDA report closes the inspection with no deficiencies found and no FDA "483" issued.

Mylan Chairman and CEO Robert J. Coury said: "I would like to thank the FDA for thoroughly reviewing this matter. The baseless speculation that was caused by a highly irresponsible and sensational newspaper article with a biased agenda was entirely unnecessary. Our customers and stakeholders recognize that there is no one in a better position to speak about issues such as these than a company's senior management or the applicable regulatory agency. It would be a mistake for anyone to rely on uninformed sources.

"Mylan's manufacturing facilities -- especially our plant in Morgantown -- have always represented the gold standard when it comes to quality. Without ever getting complacent, our entire management team and all of our employees continue to demonstrate an unyielding commitment to sustain the highest of quality standards. I would like to thank all of our employees for their continued hard work and execution, and I am pleased that this investigation is formally behind us."

Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The
'/>"/>

SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. President Clinton and Mylan Chairman and CEO Robert J. Coury Announce New Agreement to Lower Price of Treatment for Patients with Drug-Resistant HIV in Developing Countries
2. Mylan Chairman and CEO Robert J. Coury to Ring NASDAQ Stock Market Closing Bell
3. Mylan Announces Enhancements to Executive Management Team
4. Mylan Reports That the FDA Determined That All Accusations Were Unfounded
5. Mylan Reiterates and Stands Behind Its 48-Year Commitment and Track Record of Quality
6. Mylan Receives FDA Approval for Additional Strengths of the Antipsychotic Haloperidol
7. Mylan Declares Quarterly Preferred Stock Dividend
8. Mylan Receives FDA Approval for Generic Version of Thyroid Deficiency Treatment Cytomel(R)
9. Mylan Schedules Second Quarter 2009 Financial Results Conference Call and Live Webcast
10. Mylan Receives FDA Approval for Additional Strength of Generic Restoril(R)
11. Mylans Chief Operating Officer Heather Bresch to Testify Before Congress Concerning Patent Settlements Between Brand and Generic Pharmaceutical Companies and Tactics That Delay Market Entry of High Quality, Affordable Generic Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... University School of Medicine (BUSM) report variants in a ... developing Alzheimer,s disease (AD). The discovery of this novel ... that target PLXNA4 specifically. These findings appear in the ... most frequent age-related dementia affecting 5.4 million Americans including ... more than 40 percent of people age 85 and ...
(Date:7/28/2014)... The Wireline Services Market in Europe report defines and ... forecast of revenue. The Wireline services market in Europe is ... $2.4 billion by 2019, at a CAGR of 11.2%, for ... Wireline Services Market in Europe report, to get an idea ... of the segmentation in the European Wireline Services market, and ...
(Date:7/28/2014)... 28, 2014 (HealthDay News) -- A common inflammatory ... older people may increase the risk for heart ... A British study found that patients with polymyalgia ... -- conditions that affect the blood vessels. Doctors ... patients with polymyalgia rheumatica to reduce their risk ...
(Date:7/28/2014)... July 28, 2014A two-step decision tree analysis, incorporating ... and distill the many available quality standards, guidelines, ... national and international quality standards for radiation therapy, ... 2014 issue of Practical Radiation Oncology ... American Society for Radiation Oncology (ASTRO). , Guidelines, ...
(Date:7/28/2014)... Mediaplanet announced distribution of its third ... campaign that aims to raise awareness about the benefits ... TEALUX , a premium loose leaf tea shop ... readers with educational insight about the accessibility and growth ... forward and make conscious organic choices an option for ...
Breaking Medicine News(10 mins):Health News:Researchers identify potential biomarker for AD 2Health News:Europe Wireline Services Market is Expected to Reach $2.4 billion in 2019 - New Report by MicroMarket Monitor 2Health News:Europe Wireline Services Market is Expected to Reach $2.4 billion in 2019 - New Report by MicroMarket Monitor 3Health News:Europe Wireline Services Market is Expected to Reach $2.4 billion in 2019 - New Report by MicroMarket Monitor 4Health News:Inflammatory Muscle Disorder May Raise Risk for Heart Attack, Stroke 2Health News:Two-step decision tree analysis helps inform updates of RT best practices, quality standards 2Health News:Two-step decision tree analysis helps inform updates of RT best practices, quality standards 3Health News:Mediaplanet's "Organic Living" Campaign Raises Awareness About What Nature Invented, With the Help of Partner TEALUX 2
... Systems on the Role of Information Technology in Improving HealthcarePLANO, Texas, April 30 ... executive vice president and chief, ... Dr. Nathaniel Hupert, Director of The Preparedness Modeling Unit, ... Control and Prevention (CDC) and, ...
... their homes is the focus of Penn State,s portion ... that will also test the efficacy of a workplace ... "We,re seeing that stress in the workplace can create ... quality of life in families," says David Almeida, professor ...
... Practice LeaderNEW YORK, April 30 RSM McGladrey, ... a major expansion in the visibility of the ... York office. The expansion will be led by ... in the EBP sector.(Logo: http://www.newscom.com/cgi-bin/prnh/20080305/AQW023LOGO )"Companies ...
... Leaders and National Organizations Respond to Increasing Support ... DebateWASHINGTON, April 30 Men,s Health Network applauds ... today for introducing H.R. 2115, the "Men and ... would establish an Office of Men,s Health within ...
... the Newest Innovation in the Anthelios Franchise for UVA ... April 30 La Roche-Posay, the company that brought ... proudly announces the availability of Anthelios 60 Sunscreen(1) beginning ... brand,s new revolutionary sunscreen range offers ...
... WA April 30, 2009 Biogen Idec (NASDAQ: ... High-Risk AVONEX (interferon beta-1a) Multiple Sclerosis (MS) Prevention Study ... to CHAMPS (Controlled High Risk Subjects AVONEX MS Prevention ... granted approval for use in patients who experienced their ...
Cached Medicine News:Health News:Looking Forward: The Use of Health IT in Crisis 2Health News:Looking Forward: The Use of Health IT in Crisis 3Health News:Looking Forward: The Use of Health IT in Crisis 4Health News:Penn State plays integral role in $35 million stress project 2Health News:RSM McGladrey and McGladrey & Pullen LLP Announce Major Expansion of Employee Benefits Plan Practice in New York 2Health News:RSM McGladrey and McGladrey & Pullen LLP Announce Major Expansion of Employee Benefits Plan Practice in New York 3Health News:U.S. Representatives Hill and Murphy Introduce the 'Men and Families Health Care Act of 2009' 2Health News:Photos: ANTHELIOS 60 Sunscreen(1) with CELL-OX SHIELD(TM) Available May 1 Nationwide 2Health News:Photos: ANTHELIOS 60 Sunscreen(1) with CELL-OX SHIELD(TM) Available May 1 Nationwide 3Health News:First ten-year follow-up shows that treatment with AVONEX leads to long-term benefits in early multiple sclerosis patients 2
(Date:7/28/2014)... , July 28, 2014  ANI Pharmaceuticals, Inc. ... Company plans to release its second quarter and year-to-date ... the opening of the U.S. financial markets. The earnings ... section of the Company,s website, www.anipharmaceuticals.com . ... Executive Officer, and Charlotte C. Arnold , Vice ...
(Date:7/28/2014)... , July 28, 2014 PDL BioPharma, Inc. (PDL) ... will release its second quarter 2014 financial results for the ... after market close. PDL,s management will host a conference call ... discuss the financial results.  A slide presentation relating to the ... PDL website. Conference Call Details To access ...
(Date:7/28/2014)...  ProteinSimple announced today that it has launched a ... allows users to detect all proteins separated in the ... can analyze proteins without the need for an antibody.  ... analysis as we know it today. First, the Simple Western ... messy gels, no transfer tanks, no blots, no imaging ...
Breaking Medicine Technology:ANI Pharmaceuticals Schedules Conference Call for Second Quarter 2014 Financial Results 2PDL BioPharma to Announce Second Quarter 2014 Financial Results on August 11, 2014 2ProteinSimple Says "Never Run a Gel Again!" 2
Triad Plus PVP-I Scrub Winged Sponges...
Prevail is a fast-acting, effective antimicrobial gel that makes preoperative preps easier. This unique gel formulation comes in a specifically designed, easy to use applicator for excellent flow con...
The applicator is designed for a smooth delivery of the solution for surgical procedures....
... Performance Panel consists of plasma specimens with ... for antibodies to the Hepatitis C Virus. ... manufacturers and diagnostic laboratories to evaluate their ... test systems are included for comparative analysis ...
Medicine Products: